Czech deal for Nymox's Alzheimer's test:
This article was originally published in Clinica
Executive Summary
Maywood, New Jersey biotech firm Nymox Pharmaceutical has signed a marketing and distribution agreement for Prague-based KlinLab to sell its AlzheimAlert product in the Czech Republic. The test, which measures a particular biomarker in patients' urine, is offered as an aid to the diagnosis of Alzheimer's disease, and was recently CE-marked (see Clinica No 1135, p 23), although a premarket approval application was rejected in the US last year, and the company has filed an amended application.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.